Inhibitor compounds

Patent metadata

Field	Value
Publication number	US-11897877-B2
Application number	US-202117319231-A
Country	US
Kind code	B2
Filing date	May 13, 2021
Priority date	Sep 7, 2012
Publication date	Feb 13, 2024
Grant date	Feb 13, 2024

Abstract

The present invention relates to compounds of formula I

wherein R 1 , R 4 , Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

First claim

The invention claimed is:

1. A compound of formula Ic shown below:

wherein:
R 1 is selected from heteroaryl, and NR 7 R 8
and wherein R 1 is optionally substituted by one or more substituent groups selected from fluoro, chloro, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, sulphamoyl, (1-4C)alkyl, (1-4C)alkoxy, S(O) q CH 3 (where q is 0, 1, or 2), methylamino, dimethylamino, aryl, aryl(1-2C)alkyl, heteroaryl, heteroaryl(1-2C)alkyl, heterocyclyl, heterocyclyl(1-2C)alkyl, (3-8C)cycloalkyl, or (3-8C)cycloalkyl(1-2C)alkyl, and wherein any (1-4C)alkyl, (1-4C)alkoxy, aryl, heteroaryl, heterocyclyl, or (3-8C)cycloalkyl moiety present within a substituent group on R 1 is optionally further substituted by fluoro, chloro, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, sulphamoyl, (1-4C)alkyl, NR a R b , OR a , C(O)R a , C(O)OR a , OC(O)R a , N(R b )OR a , C(O)N(R b )R a , N(R b )C(O)R a , S(O) p R a (where p is 0, 1, or 2), SO 2 N(R b )R a , or N(R b )SO 2 R a , wherein R a and R b are each independently selected from H or (1-4C)alkyl;
R 3 is hydrogen, (1-4C)alkyl, or (3-6C)cycloalkyl
R 4 is hydrogen;
Ar has the formula:

wherein all of A 1 , A 2 , and A 3 are CH;
R 5 is (1-3C)alkoxy, or (1-3C)fluoroalkoxy;
R 6 is selected from heteroaryl and heterocyclyl,
and wherein R 6 is optionally further substituted by one or more substituent groups independently selected from oxo, halo, cyano, nitro, hydroxy, NR 22 R 23 , (1-4C)alkoxy, (1-4C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(1-3C)alkyl, (1-5C)alkanoyl, (1-5C)alkylsulphonyl, heterocyclyl, heterocyclyl-(1-2C)alkyl, heteroaryl, heteroaryl-(1-2C)alkyl, CONR 22 R 23 , and SO 2 NR 22 R 23 ; wherein R 22 and R 23 are each independently selected from hydrogen, (1-4C)alkyl, (3-6C)cycloalkyl, or (3-6C)cycloalkyl(1-2C)alkyl;
and wherein when said substituent group comprises an alkyl, cycloalkyl, heterocyclyl, or heteroaryl moiety then said moiety is optionally further substituted by hydroxy, fluoro, chloro, cyano, CF 3 , OCF 3 , (1-2C)alkyl, (1-2C)alkoxy, SO 2 (1-2C)alkyl, or NR e R f (where R e and R f are each independently selected from hydrogen, (1-3C)alkyl, (3-6C)cycloalkyl, or (3-6C)cycloalkyl(1-2C)alkyl);
R 8 is selected from hydrogen, (1-6C)alkyl, (1-6C)alkoxy, (3-9C)cycloalkyl, (3-9C)cycloalkyl-(1-2C)alkyl, aryl, aryl-(1-2C)alkyl, heterocyclyl, heterocyclyl-(1-2C)alkyl, heteroaryl, or heteroaryl-(1-2C)alkyl, and wherein R 8 is optionally further substituted by one or more substituents selected from hydroxy, fluoro, chloro, cyano, CF 3 , OCF 3 (1-2C)alkyl, or (1-2C)alkoxy; and
R 7 is selected from hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, or (3-6C)cycloalkyl-(1-2C)alkyl, and wherein R 7 is optionally further substituted by one or more substituents selected from hydroxy, fluoro, chloro, cyano, CF 3 , OCF 3 , (1-2C)alkyl, or (1-2C)alkoxy;
or a pharmaceutically acceptable salt or solvate thereof.

2. A compound according to claim 1 , wherein R 8 is selected from hydrogen, (1-6C)alkyl, (3-9C)cycloalkyl, (3-6C)cycloalkyl-(1-2C)alkyl, phenyl, 3 to 9 membered heterocyclyl, 3 to 9 membered heterocyclyl-(1-2C)alkyl, 5 or 6 membered heteroaryl, or 5 or 6 membered heteroaryl-(1-2C)alkyl, and wherein R 8 optionally further substituted by one or more substituents selected from hydroxy, fluoro, chloro, cyano, CF 3 , OCF 3 , (1-2C)alkyl, or (1-2C)alkoxy.

3. A compound according to claim 1 , wherein R 7 is hydrogen or (1-4C)alkyl.

4. A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt or solvate thereof, in admixture with a pharmaceutically acceptable diluent or carrier.

5. A compound according to claim 1 , wherein R 1 is selected from 5 or 6 membered heteroaryl, 3 to 9 membered heterocyclyl, or NR 7 R 8 ; and wherein R 1 is optionally substituted by one or more substituent groups selected from fluoro, chloro, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, amino, carboxy, carbamoyl, sulphamoyl, (1-4C)alkyl, (1-4C)alkoxy, S(O) q CH 3 (where q is 0, 1, or 2), methylamino, dimethylamino, phenyl, 5 or 6 membered heteroaryl, 3 to 6 membered heterocyclyl, or (3-6C)cycloalkyl,
and wherein any (1-4C)alkyl, (1-4C)alkoxy, phenyl, heteroaryl, heterocyclyl, or (3-6C)cycloalkyl group present within a substituent group on R 1 is optionally further substituted by fluoro, chloro, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, sulphamoyl, (1-4C)alkyl, NR a R b , OR a , C(O)R a , C(O)OR a , OC(O)R a , N(R b )OR a , C(O)N(R b )R a , N(R b )C(O)R a , S(O) p R a (where p is 0, 1, or 2), SO 2 N(R b )R a , or N(R b )SO 2 R a , wherein R a and R b are each independently H or (1-4C)alkyl.

6. A compound according to claim 1 , wherein R 1 is a 3 to 9 membered nitrogen-linked heterocyclyl or NR 7 R 8 ; and wherein the 3 to 9 membered nitrogen-linked heterocyclyl is optionally substituted by one or more substituent groups selected from fluoro, chloro, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, amino, carboxy, carbamoyl, sulphamoyl, (1-4C)alkyl, (1-4C)alkoxy, S(0) q CH 3 (where q is 0, 1, or 2), methylamino, dimethylamino, phenyl, 5 or 6 membered heteroaryl, 3 to 6 membered heterocyclyl, or (3-6C)cycloalkyl;
R 7 is hydrogen; and
R 8 is (1-6C)alkyl or a 3 to 9 membered heterocyclyl, each of which is optionally substituted by one or more substituents selected from hydroxyl, fluoro, chloro, cyano, CF 3 , OCF 3 , (1-2C)alkyl, or (1-2C)alkoxy.

7. A compound according to claim 1 , wherein R 1 is a 3 to 9 membered nitrogen-linked monocyclic, bicyclic, or spiro bicyclic heterocyclyl or NR 7 R 8 ; and wherein the 3 to 9 membered nitrogen-linked heterocyclyl is optionally substituted by one or more substituent groups selected from fluoro, chloro, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, amino, carboxy, carbamoyl, sulphamoyl, (1-4C)alkyl, (1-4C)alkoxy, S(0) q CH 3 (where q is 0, 1, or 2), methylamino, or dimethylamino;
R 7 is hydrogen; and
R 8 is (1-6C)alkyl or a 3 to 9 membered heterocyclyl, each of which is optionally substituted by one or more substituents selected from hydroxyl, fluoro, chloro, cyano, CF 3 , OCF 3 , (1-2C)alkyl, or (1-2C)alkoxy.

8. A compound according to claim 1 , wherein R 3 is hydrogen or methyl.

9. A compound according to claim 1 , wherein R 5 is OCH 3 .

10. A compound according to claim 1 , wherein R 6 is a 5 membered heteroaryl comprising 1, 2, or 3 nitrogen atoms;
and wherein R 6 is optionally further substituted by one or more substituent groups independently selected from halo, cyano, hydroxy, NR 22 R 23 , (1-4C)alkoxy, (1-4C)alkyl, (1-5C)alkylsulphonyl, 3 to 6 membered heterocyclyl, 3 to 6 membered heterocyclyl-(1-2C)alkyl, 5 or 6 membered heteroaryl, 5 or 6 membered heteroaryl-(1-2C)alkyl, CONR 22 R 23 , and SO 2 NR 22 R 23 ; wherein R 22 and R 23 are each independently hydrogen or (1-4C)alkyl.

11. A pharmaceutical composition according to claim 4 in a form suitable for oral use.

12. A method of treating a cancer in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt or solvate thereof; wherein the cancer is selected from lung, colon, breast, ovarian, li

Assignees

• Cancer Research Tech Ltd

Inventors

• Hoelder Swen
• Blagg Julian
• Solanki Savade
• Woodward Hannah
• Naud Sebastien Gaston Andre
• Bavetsias Vassilios
• Sheldrake Peter
• Innocenti Paolo
• Cheung Kwai-Ming J
• Atrash Butrus

Classifications

• C07D471/04 Primary

  Ortho-condensed systems · CPC title

• C07D413/14

  containing three or more hetero rings · CPC title

• C07D405/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• C07D401/14 Primary

  containing three or more hetero rings · CPC title

• C07D401/04

  directly linked by a ring-member-to-ring-member bond · CPC title